DE2549680A1 - Arzneimittel zur behandlung von ueberleitungsstoerungen des zentralen und peripheren nervensystems - Google Patents
Arzneimittel zur behandlung von ueberleitungsstoerungen des zentralen und peripheren nervensystemsInfo
- Publication number
- DE2549680A1 DE2549680A1 DE19752549680 DE2549680A DE2549680A1 DE 2549680 A1 DE2549680 A1 DE 2549680A1 DE 19752549680 DE19752549680 DE 19752549680 DE 2549680 A DE2549680 A DE 2549680A DE 2549680 A1 DE2549680 A1 DE 2549680A1
- Authority
- DE
- Germany
- Prior art keywords
- tetrahydrofuran
- ethanol
- nervous system
- central
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003169 central nervous system Anatomy 0.000 title claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 title claims description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 150000002270 gangliosides Chemical class 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 210000000944 nerve tissue Anatomy 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000014526 Conduction disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 239000003480 eluent Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- QUODEZHLKYULPH-LUWBGTNYSA-N (4S,5R,6R)-5-(ethylamino)-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound C(C)N[C@@H]1[C@H](CC(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)O QUODEZHLKYULPH-LUWBGTNYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Extraction Or Liquid Replacement (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT26323/75A IT1046051B (it) | 1975-08-13 | 1975-08-13 | Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2549680A1 true DE2549680A1 (de) | 1977-02-24 |
| DE2549680C2 DE2549680C2 (enrdf_load_stackoverflow) | 1988-05-11 |
Family
ID=11219226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752549680 Granted DE2549680A1 (de) | 1975-08-13 | 1975-11-05 | Arzneimittel zur behandlung von ueberleitungsstoerungen des zentralen und peripheren nervensystems |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JPS5234912A (enrdf_load_stackoverflow) |
| AT (1) | AT352296B (enrdf_load_stackoverflow) |
| BE (1) | BE843695A (enrdf_load_stackoverflow) |
| DE (1) | DE2549680A1 (enrdf_load_stackoverflow) |
| ES (1) | ES441233A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2320760A1 (enrdf_load_stackoverflow) |
| IT (1) | IT1046051B (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0410883A2 (en) | 1989-07-27 | 1991-01-30 | FIDIA S.p.A. | Di-lysogangliosides derivatives |
| US5264424A (en) * | 1989-11-14 | 1993-11-23 | Fidia S.P.A. | Modified gangliosides and the functional derivatives thereof |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2451194A1 (fr) * | 1979-03-16 | 1980-10-10 | Merieux Inst | Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant |
| WO1980001875A1 (fr) * | 1979-03-16 | 1980-09-18 | Merieux Inst | Nouveau medicament, notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant |
| CA1168980A (en) * | 1980-04-17 | 1984-06-12 | Rolf Schafer | Wound healing compositions |
| AU542815B2 (en) * | 1980-05-09 | 1985-03-14 | Leffler, Hakon | Carbohydrate derivatives for inhibiting bacterial adherence |
| DE3379656D1 (en) * | 1983-05-27 | 1989-05-24 | Shanksville Corp N V | Suppressing of graft rejection in organ transplantation |
| JPS59222424A (ja) * | 1983-06-01 | 1984-12-14 | Katsutaka Nagai | 神経障害疾患治療剤 |
| IT1177863B (it) * | 1984-07-03 | 1987-08-26 | Fidia Farmaceutici | Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche |
| JPH01228997A (ja) * | 1988-03-10 | 1989-09-12 | Mect Corp | シアロシルグリセライド類及びその製造方法 |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| AR241751A1 (es) * | 1989-07-12 | 1992-12-30 | Beta Lab Sa | Procedimiento para obtener mezclas de gangliosidos para el tratamiento de enfermedades psico-organicas y del caracter. |
| JPH0580009A (ja) * | 1991-09-20 | 1993-03-30 | Kubota Corp | 炭酸濃度測定方法 |
| JPH0580010A (ja) * | 1991-09-25 | 1993-03-30 | Kubota Corp | 気体中の炭酸ガス濃度測定方法 |
| RU2195296C2 (ru) * | 2000-04-12 | 2002-12-27 | Ставропольский научно-исследовательский противочумный институт | Способ получения ганглиозидов |
| RU2192871C2 (ru) * | 2000-11-22 | 2002-11-20 | Нижегородское государственное предприятие по производству бактерийных препаратов - ИмБио | Способ получения биологически активного комплекса из животного сырья для терапевтического использования |
| JP4005115B1 (ja) | 2007-02-08 | 2007-11-07 | 日本臓器製薬株式会社 | 疼痛疾患治療剤 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT127981B (de) * | 1929-06-07 | 1932-04-25 | Schering Kahlbaum Ag | Verfahren zur Herstellung eines die zentralen Tätigkeiten fördernden und regulierenden Reizstoffes. |
| CH193176A (de) * | 1936-12-08 | 1937-09-30 | Richter Arthur | Verfahren zur Gewinnung eines Wirkstoffes aus Säugetiergehirn. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3436413A (en) * | 1965-12-21 | 1969-04-01 | Canada Packers Ltd | Process for the isolation of phosphatidyl serine |
-
1975
- 1975-08-13 IT IT26323/75A patent/IT1046051B/it active Protection Beyond IP Right Term
- 1975-09-24 ES ES441233A patent/ES441233A1/es not_active Expired
- 1975-11-05 DE DE19752549680 patent/DE2549680A1/de active Granted
- 1975-12-30 FR FR7540170A patent/FR2320760A1/fr active Granted
-
1976
- 1976-07-01 BE BE168566A patent/BE843695A/xx not_active IP Right Cessation
- 1976-08-13 AT AT606976A patent/AT352296B/de not_active IP Right Cessation
- 1976-08-13 JP JP51097402A patent/JPS5234912A/ja active Granted
-
1987
- 1987-01-05 JP JP62000347A patent/JPS62187412A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT127981B (de) * | 1929-06-07 | 1932-04-25 | Schering Kahlbaum Ag | Verfahren zur Herstellung eines die zentralen Tätigkeiten fördernden und regulierenden Reizstoffes. |
| CH193176A (de) * | 1936-12-08 | 1937-09-30 | Richter Arthur | Verfahren zur Gewinnung eines Wirkstoffes aus Säugetiergehirn. |
Non-Patent Citations (4)
| Title |
|---|
| Biochemica et Biophysica Acta, 1973, 296, S.160-170 * |
| BUDDECKE E:: Grundrissd. Biochemie, Degryter, 2.Aufl., 1971, S.451 * |
| DE-Z.: Angew. Chemie, 1968, 80, DE-B.: S.89-98 * |
| Giornale di Biochemica 1964, H.5, S.315-321 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0410883A2 (en) | 1989-07-27 | 1991-01-30 | FIDIA S.p.A. | Di-lysogangliosides derivatives |
| US5264424A (en) * | 1989-11-14 | 1993-11-23 | Fidia S.P.A. | Modified gangliosides and the functional derivatives thereof |
| US5424294A (en) * | 1989-11-14 | 1995-06-13 | Fidia S.P.A. | Modified gangliosides and the functional derivatives thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AT352296B (de) | 1979-09-10 |
| JPS6256134B2 (enrdf_load_stackoverflow) | 1987-11-24 |
| ES441233A1 (es) | 1977-03-16 |
| FR2320760A1 (fr) | 1977-03-11 |
| ATA606976A (de) | 1979-02-15 |
| JPS6250450B2 (enrdf_load_stackoverflow) | 1987-10-24 |
| JPS5234912A (en) | 1977-03-17 |
| DE2549680C2 (enrdf_load_stackoverflow) | 1988-05-11 |
| JPS62187412A (ja) | 1987-08-15 |
| IT1046051B (it) | 1980-06-30 |
| FR2320760B1 (enrdf_load_stackoverflow) | 1978-11-17 |
| BE843695A (fr) | 1976-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2549680A1 (de) | Arzneimittel zur behandlung von ueberleitungsstoerungen des zentralen und peripheren nervensystems | |
| DE3750785T2 (de) | Oligosaccharide von Heparin mit einer Affinität für Faktoren von Zellwachstum. | |
| DE69328192T4 (de) | Injizierbare Arzneizubereitungen enthaltend Taxanderivate | |
| EP0143977A2 (de) | Bilobalid zur Anwendung als Therapeutischer Wirkstoff | |
| EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
| DE3537656C2 (enrdf_load_stackoverflow) | ||
| DE3523021A1 (de) | Verwendung von gangliosiden zur schmerzbehandlung | |
| DE2413642A1 (de) | Gegen allergien und entzuendungen wirkendes und als immunsuppressivum wirksames medikament | |
| DD144719A5 (de) | Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit | |
| DE69019122T2 (de) | Stabilisierung und Wartung der biologischen Aktivität des Nervenwachstumsfaktor unter Benützung von natürlichen Gangliosiden oder deren Derivaten. | |
| DE2433209A1 (de) | Hitzestabile plasmaproteinloesungen, verfahren zu ihrer herstellung und arzneipraeparate | |
| DE3486191T2 (de) | Arzneimittel mit systematischer anticholinesterasischer, agonistisch-cholinergischer und antimuskariner Wirkung. | |
| DE69307895T2 (de) | Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin | |
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE3787971T2 (de) | Aktives prinzip, isoliert aus haigeweben. | |
| DE69115528T2 (de) | Neue pharmazeutische Verwendungen von Forskolin-Derivaten | |
| DE602004006024T2 (de) | Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose | |
| DE2723451A1 (de) | Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln | |
| DE3914354C1 (enrdf_load_stackoverflow) | ||
| US6620793B2 (en) | Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury | |
| DE68911049T2 (de) | Therapeutische Verwendung des Isopropylesterderivates von Monosialogangliosiden bei Erkrankungen des Nervensystems, begleitet von Entzündungen. | |
| CH654316A5 (de) | 4-amino-1beta-d-ribofuranosyl-1h-imidazo(4,5-c)pyridin als mittel fuer die behandlung von entzuendungen. | |
| DE60122384T2 (de) | Verfahren zur herstellung einer beständige pharmazeutische form von paclitaxel | |
| DE3781045T2 (de) | Antirheumatisches arzneimittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8128 | New person/name/address of the agent |
Representative=s name: SCHWABE, H., DIPL.-ING. SANDMAIR, K., DIPL.-CHEM. |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |